A phase I, first-in-human dose-escalation and triple-negative breast cancer dose-expansion study of a TROP2-ADC F0024 (FDA018)
European Journal of Cancer · 2026-11 · 248 · 117063
DOI: 10.1016/j.ejca.2026.117063 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift European Journal of Cancer, 2026-11. Verfasst von Yiqun Du und 11 weiteren Autor:innen. Beteiligte Einrichtung: Phase I Unit, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai,…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Antigens, Neoplasm, Cell Adhesion Molecules, Antineoplastic Agents. Die Arbeit nennt 28 Literaturangaben. Gefördert von: Science and Technology Commission of Shanghai Municipality.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Phase I Unit, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
- Department II of Breast, Linyi Cancer Hospital, Linyi, China.
- Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
- Department of Medical Oncology, Fujian Cancer Hospital, Fuzhou, China.
- Phase I Unit, Fujian Cancer Hospital, Fuzhou, China.
- Department of Medical Oncology, The First Affiliated Hospital of Xiamen University, Xiamen, China.
Förderung
- Science and Technology Commission of Shanghai Municipality
Zitieren
APA
Du, Y., Meng, Y., Liu, X., Wang, J., Wang, Y., Wu, F., Chen, Y., Chen, L., Qing, L., Sun, W., Liu, K., & Zhang, J. (2026). A phase I, first-in-human dose-escalation and triple-negative breast cancer dose-expansion study of a TROP2-ADC F0024 (FDA018). European Journal of Cancer, 248, 117063. https://doi.org/10.1016/j.ejca.2026.117063
Vancouver
Du Y, Meng Y, Liu X, Wang J, Wang Y, Wu F, et al. A phase I, first-in-human dose-escalation and triple-negative breast cancer dose-expansion study of a TROP2-ADC F0024 (FDA018). European Journal of Cancer. 2026;248:117063. doi:10.1016/j.ejca.2026.117063
BibTeX
@article{Du2026,
author = {Du, Yiqun and Meng, Yanchun and Liu, Xiaojun and Wang, Jingfen and Wang, Ying and Wu, Fan and Chen, Yu and Chen, Lilin and Qing, Lihua and Sun, Wenyi and Liu, Kezhen and Zhang, Jian},
title = {A phase I, first-in-human dose-escalation and triple-negative breast cancer dose-expansion study of a TROP2-ADC F0024 (FDA018)},
journal = {European Journal of Cancer},
year = {2026},
volume = {248},
pages = {117063},
doi = {10.1016/j.ejca.2026.117063}
}
EUVIMED